Glutathione in cancer progression and chemoresistance: an update
Redox Experimental Medicine · 2023
DOI: 10.1530/rem-22-0023 ↗Kurz gefasst
Fachartikel in der Zeitschrift Redox Experimental Medicine, 2023. Verfasst von Giulia Elda Valenti und 4 weiteren Autor:innen. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 106 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Glutathione (GSH) is one of the most important components of the cellular antioxidant system, and it is able to exert several pleiotropic functions influencing cell growth, proliferation, adaptation and death. It has been demonstrated that changes in GSH levels underlie the pathogenesis of many human diseases, including cancer. In detail, although on one hand GSH homeostasis plays a protective role from the onset of cancer, on the other, it is involved in cancer progression and in therapy resistance. In this review, after a brief report on the physiological role of GSH, we have focused the attention on its role in cancer and refractoriness to anticancer therapy giving an update on the preclinical and clinical studies relied on the compounds targeting GSH system. Based on these considerations, a deeper knowledge of GSH-dependent network can be crucial to identify new strategies for preventing and/or curing cancer.
Zitieren
APA
Valenti, G. E., Tasso, B., Traverso, N., Domenicotti, C., & Marengo, B. (2023). Glutathione in cancer progression and chemoresistance: an update. Redox Experimental Medicine. https://doi.org/10.1530/rem-22-0023
Vancouver
Valenti GE, Tasso B, Traverso N, Domenicotti C, Marengo B. Glutathione in cancer progression and chemoresistance: an update. Redox Experimental Medicine. 2023. doi:10.1530/rem-22-0023
BibTeX
@article{Valenti2023,
author = {Valenti, Giulia Elda and Tasso, Bruno and Traverso, Nicola and Domenicotti, Cinzia and Marengo, Barbara},
title = {Glutathione in cancer progression and chemoresistance: an update},
journal = {Redox Experimental Medicine},
year = {2023},
doi = {10.1530/rem-22-0023}
}
EUVIMED